Research programme: cancer therapies - H3 Biomedicine

Drug Profile

Research programme: cancer therapies - H3 Biomedicine

Alternative Names: SF3B1 inhibitors - H3 Biomedicine; SF3B1 modulator - H3 Biomedicine; Splicing factor inhibitor - H3 Biomedicine; Splicing inhibitors - H3 Biomedicine

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator H3 Biomedicine
  • Developer H3 Biomedicine; University of British Columbia; Vancouver Coastal Health
  • Class Antineoplastics
  • Mechanism of Action Estrogen receptor antagonists; Phosphoprotein modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 24 Jul 2017 Preclinical trials in Cancer in Canada (PO)
  • 24 Jul 2017 Pharmacodynamics data from a preclinical trial in Bladder cancer released by H3 Biomedicine
  • 01 Jun 2017 Pharmacodynamics data from a preclinical trial released by H3 Biomedicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top